Vis enkel innførsel

dc.contributor.authorBerg, Kristin Sandal
dc.contributor.authorSeines, Ellisiv
dc.contributor.authorGál, Peter
dc.contributor.authorLøberg-Emanuelsen, Lise
dc.contributor.authorStubhaug, Audun
dc.contributor.authorNielsen, Erik Waage
dc.contributor.authorSpigset, Olav
dc.date.accessioned2024-05-24T11:27:47Z
dc.date.available2024-05-24T11:27:47Z
dc.date.issued2024-04-10
dc.description.abstractNo previous studies have investigated the systemic absorption of bupivacaine when used topically for posttonsillectomy pain. The present study was undertaken to investigate the pharmacokinetics of bupivacaine after administration by a swab in the tonsillar fossae over 4 min after tonsillectomy. Eleven adult patients undergoing elective tonsillectomy were recruited. After removal of both tonsils, each of the two tonsillar fossae was covered with a swab moistened with 2 mL of bupivacaine 5 mg/mL, that is, a total of 20 mg bupivacaine. Blood samples were drawn after 0, 5, 10, 20, 30, 45, and 60 min. Bupivacaine was analyzed with an ultra-high-performance liquid chromatography–tandem mass spectrometry method. The highest single measured bupivacaine serum concentration was 23.2 ng/mL and took place 10 min after drug administration. Mean (±SD) C<sub>max</sub> was 11.4 ± 6.0 ng/mL and mean t<sub>max</sub> was 11.3 ± 4.7 min. Mean t<sub>1/2</sub> was 31.6 ± 9.3 min. As the toxic concentration threshold has been reported to be in the interval 1500–4500 ng/mL, the concentrations measured were well below 2% of the lowest cited toxic threshold. In conclusion, this study shows that applying 4 mL of bupivacaine 5 mg/mL by a swab in the tonsillar fossae posttonsillectomy yields very low plasma concentrations, suggesting its safe application without any risk of systemic toxic effects.en_US
dc.identifier.citationBerg, Seines, Gál, Løberg-Emanuelsen, Stubhaug, Nielsen, Spigset. Absorption and pharmacokinetics of bupivacaine after bilateral topical administration in tonsillar fossae for posttonsillectomy pain relief. Pharmacology Research & Perspectives. 2024;12(2)en_US
dc.identifier.cristinIDFRIDAID 2264771
dc.identifier.doi10.1002/prp2.1196
dc.identifier.issn2052-1707
dc.identifier.urihttps://hdl.handle.net/10037/33607
dc.language.isoengen_US
dc.publisherWileyen_US
dc.relation.journalPharmacology Research & Perspectives
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2024 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0en_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)en_US
dc.titleAbsorption and pharmacokinetics of bupivacaine after bilateral topical administration in tonsillar fossae for posttonsillectomy pain reliefen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Med mindre det står noe annet, er denne innførselens lisens beskrevet som Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)